Journal: International Journal of Cancer. Journal International du Cancer

Article Title: Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model

doi: 10.1002/ijc.26379

Figure Lengend Snippet: CHI3L1 increases the expression of CCL2, CXCL2 and MMP-9. Macrophages from normal mice were cultured overnight with either 1 ng/mL or 5 ng/mL rmCHI3L1 alone (A,C,E) or in combination with LPS (1 μg/mL) (B,D,F) and cell-free supernatants were analyzed by ELISA for CCL2 (A–B) ; CXCL2 (C–D) or MMP-9 (E–F). N= 10 mice/group, (A–B) *p<0.0015, **p<0.0001, (CD)*p<0.0005, ** p<0.0002, and (E–F) *p<0.004, **p<0.0016.

Article Snippet: Cell culture supernatants and sera from control and mammary tumor bearers were analyzed for protein expression by ELISA for CCL2, CXCL2 and IFN-γ (BD Biosciences, San Jose, CA), MMP-9 and CHI3L1 (R&D Systems) according to the manufacturer's instructions.

Techniques: Expressing, Cell Culture, Enzyme-linked Immunosorbent Assay

Journal: International Journal of Cancer. Journal International du Cancer

Article Title: Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model

doi: 10.1002/ijc.26379

Figure Lengend Snippet: Silencing CHI3L1 decreases secretion of proinflammatory molecules by macrophages. (A) In vitro treatment of LPS (1 μg/mL) stimulated macrophages from 5-week DA-3 tumor bearers with 50 nM CHI3L1 siRNA analyzed by qRT-PCR for CHI3L1 gene expression and protein expression as determined by ELISA (B). (C–E) Purified macrophages from 5-week DA-3 tumor bearers were cultured with 50 nM CHI3L1 siRNA or 50 NM nontarget siRNA in the presence of LPS and cell-free culture supernatants analyzed for CCL2 (C), CXCL2 (D) and MMP-9 (E). N = 5 mice/group, *p < 0.05, Student's t-test

Article Snippet: Cell culture supernatants and sera from control and mammary tumor bearers were analyzed for protein expression by ELISA for CCL2, CXCL2 and IFN-γ (BD Biosciences, San Jose, CA), MMP-9 and CHI3L1 (R&D Systems) according to the manufacturer's instructions.

Techniques: In Vitro, Quantitative RT-PCR, Expressing, Enzyme-linked Immunosorbent Assay, Purification, Cell Culture

Journal: International Journal of Cancer. Journal International du Cancer

Article Title: Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model

doi: 10.1002/ijc.26379

Figure Lengend Snippet: In vivo treatment with chitin decreases CHI3L1, CCL2, CXCL2 and MMP-9 expression in DA-3 tumor-bearing mice. (A) Serum from 2- and 5-week DA-3 tumor bearers either untreated or chitin treated (1 mg/mouse) was analyzed for CHI3L1 expression by ELISA. (B–C) Splenocytes (B) and splenic macrophages (C) from untreated or chitin treated 5-week DA-3 tumor-bearing mice were cultured overnight in the presence or absence of LPS (1 μg/mL) and cell-free supernatants were analyzed for CHI3L1 by ELISA. (D–F) Purified macrophages and T cells from spleens of 5-week DA-3 tumor-bearing mice, untreated, or chitin treated were cultured overnight with mitogens as described, and cell-free supernatants were analyzed by ELISA for CCL2 (D), CXCL2 (E) and MMP-9 (F). Data shown are the results of three independent experiments with N= 4 mice/group; *p<0.003, **p<0.002, Student's t-test

Article Snippet: Cell culture supernatants and sera from control and mammary tumor bearers were analyzed for protein expression by ELISA for CCL2, CXCL2 and IFN-γ (BD Biosciences, San Jose, CA), MMP-9 and CHI3L1 (R&D Systems) according to the manufacturer's instructions.

Techniques: In Vivo, Expressing, Enzyme-linked Immunosorbent Assay, Cell Culture, Purification

Journal: Reproductive Biology and Endocrinology : RB&E

Article Title: The ameliorative effect of ellagic acid on di-(2-ethylhexyl) phthalate-induced testicular structural alterations, oxidative stress, inflammation and sperm damages in adult mice

doi: 10.1186/s12958-021-00830-0

Figure Lengend Snippet: The effect of EA on serum testosterone, LH and FSH levels in mice exposed to DEHP. Values are means ± S.D. ( n = 7). * p < 0.05 as compared to control group. # p < 0.05 as compared to DEHP group

Article Snippet: The serum levels of testosterone, LH and FSH were measured using mouse testosterone, LH and FSH ELISA kits (MyBioSource Co, cat num: MBS843463, MBS041300 and MBS2507988, respectively).

Techniques: Control

Journal: Journal of Orthopaedic Surgery and Research

Article Title: Downregulation of lncRNA NEAT1 interacts with miR-374b-5p/PGAP1 axis to aggravate the development of osteoarthritis

doi: 10.1186/s13018-023-04147-z

Figure Lengend Snippet: Silencing of NEAT1 promotes apoptosis and inflammatory responses in LPS-induced chondrocytes. A The expression of NEAT1 in chondrocytes after transfection with NEAT1 siRNA-1/-2/-3 or NC siRNA was detected via qRT-PCR (analyzed by One-way ANOVA followed by Tukey's multiple comparisons test). * P < 0.05, ** P < 0.01, *** P < 0.001 vs. NC siRNA. B The expression of NEAT1 in LPS-induced chondrocytes after transfection with NEAT1 siRNA or NC siRNA was detected via qRT-PCR (analyzed by Student’s t -test). ** P < 0.01 vs. LPS + NC siRNA. C The viability of LPS-induced chondrocytes transfected with NEAT1 siRNA/NC siRNA was measured by CCK-8 assay (analyzed by Student’s t -test). * P < 0.05, *** P < 0.001 vs. LPS + NC siRNA. Cell frequency ( D ) and apoptosis rate ( E ) of LPS-induced chondrocytes transfected with NEAT1 siRNA/NC siRNA were calculated via flow cytometry analysis (analyzed by Student’s t -test). * P < 0.05, *** P < 0.001 vs. LPS + NC siRNA. F The protein levels of Caspase3, Caspase9, Cyclin A1, Cyclin B1 and Cyclin D2 in LPS-induced chondrocytes transfected with NEAT1 siRNA/NC siRNA were determined via western blotting (analyzed by Student’s t -test). * P < 0.05, *** P < 0.001 vs. LPS + NC siRNA. G The levels of TNF-α, IL-1β and IL-6 in LPS-induced chondrocytes transfected with NEAT1 siRNA/NC siRNA were determined via ELISA (analyzed by Student’s t -test). *** P < 0.001 vs. LPS + NC siRNA. Error bars represented as the means ± standard deviation (SD)

Article Snippet: Human TNF-α, IL-1β and IL-6 ELISA Kits, and rat TNF-α, IL-1β and IL-6 ELISA Kits were purchased from ImmunoWay Biotechnology (Plano, TX, USA).

Techniques: Expressing, Transfection, Quantitative RT-PCR, CCK-8 Assay, Flow Cytometry, Western Blot, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Journal of Orthopaedic Surgery and Research

Article Title: Downregulation of lncRNA NEAT1 interacts with miR-374b-5p/PGAP1 axis to aggravate the development of osteoarthritis

doi: 10.1186/s13018-023-04147-z

Figure Lengend Snippet: MiR-374b-5p upregulation accelerates apoptosis and inflammatory reactions in LPS-induced chondrocytes. A The expression of miR-374b-5p in LPS-induced chondrocytes after transfection of miR-374b-5p mimic or NC mimic was detected by qRT-PCR. *** P < 0.001 vs. LPS + NC mimic. B The viability of LPS-induced chondrocytes transfected with miR-374b-5p mimic/NC mimic was measured by CCK-8 assay. ** P < 0.01, *** P < 0.001 vs. LPS + NC mimic. Cell frequency ( C ) and apoptosis rate ( D ) of LPS-induced chondrocytes transfected with miR-374b-5p mimic/NC mimic were calculated via flow cytometry analysis. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. LPS + NC mimic. E The protein levels of Caspase3, Caspase9, Cyclin A1, Cyclin B1 and Cyclin D2 in LPS-induced chondrocytes transfected with miR-374b-5p mimic/NC were determined via western blotting. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. LPS + NC mimic. F The levels of TNF-α, IL-1β and IL-6 in LPS-induced chondrocytes transfected with miR-374b-5p mimic/NC were determined via ELISA. ** P < 0.01, *** P < 0.001 vs. LPS + NC mimic. Error bars represented as the means ± standard deviation (SD). Data were all analyzed by Student’s t -test

Article Snippet: Human TNF-α, IL-1β and IL-6 ELISA Kits, and rat TNF-α, IL-1β and IL-6 ELISA Kits were purchased from ImmunoWay Biotechnology (Plano, TX, USA).

Techniques: Expressing, Transfection, Quantitative RT-PCR, CCK-8 Assay, Flow Cytometry, Western Blot, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Journal of Orthopaedic Surgery and Research

Article Title: Downregulation of lncRNA NEAT1 interacts with miR-374b-5p/PGAP1 axis to aggravate the development of osteoarthritis

doi: 10.1186/s13018-023-04147-z

Figure Lengend Snippet: MiR-374b-5p regulates PGAP1 expression to affect the apoptosis and inflammation in LPS-induced chondrocytes. A The expression of PGAP1 in LPS-induced chondrocytes transfected with OE-NC, OE-PGAP1, OE-NC + NC mimic or OE-PGAP1 + miR-374b-5p mimic was detected via qRT-PCR. B The viability of LPS-induced chondrocytes transfected with OE-NC, OE-PGAP1, OE-NC + NC mimic or OE-PGAP1 + miR-374b-5p mimic was measured by CCK-8 assay. Cell frequency ( C ) and apoptosis rate ( D ) of LPS-induced chondrocytes transfected with OE-NC, OE-PGAP1, OE-NC + NC mimic or OE-PGAP1 + miR-374b-5p mimic were calculated via flow cytometry analysis. E The protein levels of Caspase3, Caspase9, Cyclin A1, Cyclin B1 and Cyclin D2 in LPS-induced chondrocytes transfected with OE-NC, OE-PGAP1, OE-NC + NC mimic or OE-PGAP1 + miR-374b-5p mimic were determined via western blotting. F The levels of TNF-α, IL-1β and IL-6 in LPS-induced chondrocytes transfected with OE-NC, OE-PGAP1, OE-NC + NC mimic or OE-PGAP1 + miR-374b-5p mimic were determined via ELISA. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. LPS + OE-NC. # P < 0.05, ## P < 0.01, ### P < 0.001 vs. LPS + OE-PGAP1. Error bars represented as the means ± standard deviation (SD). Data were all analyzed by One-way ANOVA followed by Tukey's multiple comparisons test

Article Snippet: Human TNF-α, IL-1β and IL-6 ELISA Kits, and rat TNF-α, IL-1β and IL-6 ELISA Kits were purchased from ImmunoWay Biotechnology (Plano, TX, USA).

Techniques: Expressing, Transfection, Quantitative RT-PCR, CCK-8 Assay, Flow Cytometry, Western Blot, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Journal of Orthopaedic Surgery and Research

Article Title: Downregulation of lncRNA NEAT1 interacts with miR-374b-5p/PGAP1 axis to aggravate the development of osteoarthritis

doi: 10.1186/s13018-023-04147-z

Figure Lengend Snippet: Indicators in an OA rat model. A – C The expression of NEAT1, miR-374b-5p and PGAP1 in the cartilage tissues of OA rats was detected via qRT-PCR. *** P < 0.001 vs. sham. D The pathological changes between the rats in the sham and model groups were observed via HE staining. E The levels of TNF-α, IL-1β and IL-6 in the serum of OA rats were determined via ELISA. ***P < 0.001 vs. sham. The animal experiments were performed in 5 rats in each group. Error bars represented as the means ± standard deviation (SD). Data were all analyzed by Student’s t -test

Article Snippet: Human TNF-α, IL-1β and IL-6 ELISA Kits, and rat TNF-α, IL-1β and IL-6 ELISA Kits were purchased from ImmunoWay Biotechnology (Plano, TX, USA).

Techniques: Expressing, Quantitative RT-PCR, Staining, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: Nucleotide sequences of primers used to amplify genes differentiated in the study samples (group A and B) from the control samples (group C) by the RT-qPCR.

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Control, Sequencing

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: Microarray expression profile of genes associated with drug resistance differentiating between the ovarian cancer samples (groups A and B) from control samples (group C) (p <0.05) for: UBA2 , ubiquitin-like modifier-activating enzyme 2; GLO1 , glyoxalase I; STATH , statherin; TUFT1, tuftelin 1; RIC8A , RIC8 guanine nucleotide exchange factor B; ABCC5 , ATP-binding cassette subfamily C member 5; HPD , 4-hydroxyphenylpyruvate dioxygenase; GBF1 , Golgi brefeldin A-resistant guanine nucleotide exchange factor 1; (+), overexpression in comparison with the control (–);, downregulation in comparison with the control.

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Microarray, Expressing, Control, Ubiquitin Proteomics, Binding Assay, Over Expression, Comparison

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: Expression pattern of selected genes in the study groups (A and B) in comparison with the control group (C) obtained by RT-qPCR, including patients undergoing chromotherapy (in A group) and menopause (total and in A group).

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Expressing, Comparison, Control

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: Changes in miRNA expression levels for differentiating ovarian cancer samples (groups A and B) from control samples (group C) that are potentially involved in regulating the expression of the selected transcripts, for UBA2 , ubiquitin-like modifier-activating enzyme 2; GLO1 , glyoxalase I; STATH , statherin, TUFT1 , tuftelin 1; RIC8A , RIC8 guanine nucleotide exchange factor B; ABCC5 , ATP-binding cassette subfamily C member 5; HPD , 4-hydroxyphenylpyruvate dioxygenase; GBF1 , Golgi brefeldin A-resistant guanine nucleotide exchange factor 1. (+), overexpression in comparison with the control; (-), downregulation in comparison with the control.

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Expressing, Control, Ubiquitin Proteomics, Binding Assay, Over Expression, Comparison

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: miRNAs affecting the transcriptional activity of genes differentiating ovarian cancer samples compared to the control samples. UBA2 , ubiquitin-like modifier-activating enzyme 2; GLO1 , glyoxalase I; STATH , statherin, TUFT1 , tuftelin 1; RIC8A , RIC8 guanine nucleotide exchange factor B; ABCC5 , ATP-binding cassette subfamily C member 5; HPD , 4-hydroxyphenylpyruvate dioxygenase; GBF1 , Golgi brefeldin A-resistant guanine nucleotide exchange factor 1.

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Activity Assay, Control, Ubiquitin Proteomics, Binding Assay

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: Differences in the concentration of UBA2, GLO1, TUFT1, and STATH in the study (A and B) and control (C) groups obtained by ELISA assay, and their relationship with chemotherapy resistance including patients undergoing chromotherapy (in A group) and menopause (total and in A group).

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Concentration Assay, Control, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: Summarizing the changes in the expression of the selected mRNA-miRNA-protein for differentiating ovarian cancer samples (groups A and B) from control samples (group C).

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Expressing, Control

Journal: Frontiers in Oncology

Article Title: Clinical and molecular evaluation of patients with ovarian cancer in the context of drug resistance to chemotherapy

doi: 10.3389/fonc.2022.954008

Figure Lengend Snippet: Correlation between levels of biochemical and molecular markers, as values of Spearman’s R coefficients and the significance p -value, among women with ovarian cancer (groups A and B) compared with those of women in the control group (C).

Article Snippet: To determine the concentration of the analyzed proteins, we used the UBA2 Elisa kit (Human ubiquitin-like modifier-activating enzyme 2 ELISA Kit, MyBioSource, Inc. San Diego, CA 92195-3308, USA, Cat. no. MBS9317388), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA,Cat. no. MBS761164), Human GLO1 ELISA Kit (MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2533426), and TUFT ELISA kit (Human Tuftelin (TUFT) ELISA Kit, MyBioSource, Inc., Inc., San Diego, CA, USA, Cat. no. MBS2104898) in accordance with the manufacturer’s recommendation.

Techniques: Control